Johnson & Johnson announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., adding the investigational bispecific antibody OLN324 to its retinal disease pipeline. The company also plans to enter into a separate development funding agreement with Blackstone Life Sciences to support the phase 3 clinical development of OLN324, contingent upon closing of the acquisition, according to a company press release.
OLN324 is an investigational bispecific antibody designed to target vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), two pathways involved in retinal vascular disease. According to Johnson & Johnson, OLN324 combines high Ang2 potency with a small protein format, known as a minibody, that could improve retinal fluid control. The therapy is being developed for conditions including wet AMD and diabetic macular edema.
Under the agreement, Johnson & Johnson will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments up to approximately $1.125billion. The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.
Under the separate funding agreement, Blackstone will provide Johnson & Johnson with $750 million over multiple years to fully fund the phase 3 development of OLN324. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments, as well as single-digit royalties. OM


